Your browser doesn't support javascript.
loading
Use of proton pump inhibitors after laparoscopic gastric bypass and sleeve gastrectomy: a nationwide register-based cohort study.
Gormsen, Johanne; Sanberg, Jonas; Gögenur, Ismail; Helgstrand, Frederik.
Afiliação
  • Gormsen J; Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge, Denmark. jgor@regionsjaelland.dk.
  • Sanberg J; Upper GI and HPB Section, Department of Surgery, Odense University Hospital, Odense, Denmark.
  • Gögenur I; Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge, Denmark.
  • Helgstrand F; Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge, Denmark.
Int J Obes (Lond) ; 2024 Jul 23.
Article em En | MEDLINE | ID: mdl-39043831
ABSTRACT
BACKGROUND/

OBJECTIVES:

L-RYGB and L-SG are the dominant bariatric procedures worldwide. While L-RYGB is an effective treatment of coexisting gastroesophageal reflux disease (GERD), L-SG is associated with an increased risk of de-novo or worsening of GERD. The study aimed to evaluate the long-term use of proton pump inhibitors (PPI) following laparoscopic Roux-en-Y gastric bypass (L-RYGB) and sleeve gastrectomy (L-SG). SUBJECTS/

METHODS:

This nationwide register-based study included all patients undergoing L-RYGB or L-SG in Denmark between 2008 and 2018. In total, 17,740 patients were included in the study, with 16,096 and 1671 undergoing L-RYGB and L-SG, respectively. The median follow up was 11 years after L-RYGB and 4 years after L-SG. Data were collected through Danish nationwide health registries. The development in PPI use was assessed through postoperative redeemed prescriptions. GERD development was defined by a relevant diagnosis code associated with gastroscopy, 24 h pH measurement, revisional surgery or anti-reflux surgery. The risk of initiation of PPI treatment or GERD diagnosis was evaluated using Kaplan-Meier plots and COX regression models. The risk of continuous PPI treatment was examined using logistic regression modeling.

RESULTS:

The risk of initiating PPI treatment was significantly higher after L-SG compared with L-RYGB (HR 7.06, 95% CI 6.42-7.77, p < 0.0001). The risk of continuous PPI treatment was likewise significantly higher after L-SG (OR 1.45, 95% CI 1.36-1.54, p < 0.0001). The utilization of PPI consistently increased after both procedures. The risk of GERD diagnosis was also significantly higher after L-SG compared with L-RYGB (HR 1.93, 95% CI 1.27-2.93, p < 0.0001).

CONCLUSIONS:

The risk of initiating and continuing PPI treatment was significantly higher after L-SG compared with L-RYGB, and a continuous increase in the utilization of PPI was observed after both procedures.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article